CAS: 19237-84-4; (4-(4-Amino-6,7-Dimethoxyquinazolin-2-yl)Piperazin-1-yl)(Furan-2-yl)Methanone Hydrochloride

上下游产品

CAS号67817-59-8 Methyl N-(3,4-D... | CAS号527-69-5 糠酰氯 | CAS号123-51-3 异戊醇 | CAS号60547-97-9 2-(1-哌嗪基)-4-氨基-... | CAS号26961-27-3 2-氨基-4,5-二甲氧基苯腈 | CAS号43091-89-0 3,4-Dimethoxy-6... | CAS号67817-56-5 N-(2-cyano-4,5-... | CAS号63590-64-7 特拉唑嗪

Methyl N-(3,4-Dimethoxy-6-Cyanophenyl)-<4-(2-Furoyl)Piperazin-1-Yl>Thioformamidate置于ammonium Chloride体系中,用 Formamide 用作溶剂,化学反应 20.0H,以86%的收率获得盐酸哌唑嗪
参考文献:哌唑嗪的新实用合成
标题:哌唑嗪的新实用合成
摘要:已经描述了新的四步合成哌唑嗪2-[4-(2-呋喃基)哌嗪-1-基]-4-氨基-6,7-二甲氧基喹唑啉.该方法也适用于制备其他取代的4-氨基喹唑啉.在每个步骤中产率都很高,并且反应容易进行.在最后一步中直接获得了高纯度的哌唑嗪盐酸盐.
Doi:10.1002/jhet.5570170436

专利信息

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-6387893-B1
优先权日:1999-09-30
标题 :Spirotricyclic substituted azacycloalkane derivatives and uses thereof
发明人：EVANS BEN E; HOFFMAN JACOB M; GILBERT KEVIN F; RITTLE KENNETH E
权利人:MERCK & CO INC
摘要:Spirotricyclic azacycloalkyl compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds is also described. One application of these compounds, which are alpha 1a adrenergic receptor antagonists, is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:US-6130218-A
优先权日:1996-12-20
标 题 :Polymorphic form of doxazosin mesylate (Form I)
发明人：MOERSDORF JOHANN PETER; GRAFE INGOMAR
权利人:HEUMANN PHARMA GMBH & CO
摘要:A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 15.40°, 16.85°, 18.06°, 24.15° and 25.81°. Owing to its crystalline properties, the new form of doxazosin mesylate according to the invention has surprising advantages both with regard to its synthesis and for pharmaceutical processing into solid dosage forms. A process for preparing the new form of doxazosin mesylate and pharmaceutical compositions comprising the new form of doxazosin mesylate are also described.

专利号:US-6133269-A
优先权日:1996-12-20
标题:Polymorphic form of doxazosin mesylate (form II)
发明人：MOERSDORF JOHANN PETER; GRAFE INGOMAR
权利人:HEUMANN PHARMA GMBH & CO
摘要:A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 10.68°, 14.45°, 17.37°, 23.45°, 23.82° and 24.30 °. Owing to its crystalline properties, the new form of doxazosin mesylate according to the invention has surprising advantages both with regard to its synthesis and for pharmaceutical processing into solid dosage forms. A process for preparing the new form of doxazosin mesylate and pharmaceutical compositions comprising the new form of doxazosin mesylate are also described.

专利号:US-6232318-B1
优先权日:1998-11-12
标 题:Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists
发明人：NERENBERG JENNIE B; BOCK MARK G
权利人:MERCK & CO LTD
摘要:Novel pyrimidinedione compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:US-6326372-B1
优先权日:1999-09-30
标 题:Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
发明人：EVANS BEN E; GILBERT KEVIN F
权利人:MERCK & CO INC
摘要:Lactam and cyclic urea derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.